West Virginia University Logo

Disease Site: Lymphoma

12 protocol(s) meet the specified criteria

  • ACE-LY-308A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
  • BMTCTN1101A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies
  • C34005A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy
  • CC-5013-NHL-008A Phase III Randomized Study of Lenalidomide Plus Rituximab Maintence Therapy Followed By Lenalidomide Single-Agent Maintenance versus Rituximab Maintenance in Subjects with Relapsed refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
  • COG-AHOD1331AHOD1331 - A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
  • CONNECT-MDS-AMLCONNECT MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • EFT508-0002A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Hematological Malignancies.
  • MK3475-204Phase III, Randomized, Open-Label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkins Lymphoma
  • PCYC-1140-IMA Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)
  • PCYC-1141-CAA Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
  • WVU11310Once daily intravenous Busulfex as part of reduced toxicity conditioning for patients with relapsed/refractory Hodgkin and non-Hodgkin lymphomas undergoing allogeneic hematopoietic cell transplantation - A multicenter phase II study